Fig. 5.

Body surface area (BSA) progress during the study. BSA decreased during treatment with brodalumab by 20.1%-points from 20.8 (± 10.6) % before the start of therapy (baseline, BL) to 0.7 (± 1.9) % at the last visit, i.e., week (W) 52